Rhythm Pharmaceuticals anuncia la autorización de la Comisión Europea de IMCIVREE® (setmelanotida)▼ para el tratamiento de la obesidad y el control del hambre asociados a la deficiencia de POMC, PCSK1 y LEPR

Ads

You May Also Like

National Cancer Institute selects Apexian Pharmaceuticals to participate in the Small Business Innovation Research (SBIR) Initiative program

Indianapolis, Indiana, USA, Sept. 27, 2017 (GLOBE NEWSWIRE) --                                                                                                                                           FOR IMMEDIATE RELEASE National ...